Hyperthermia enhances the effect of β-lapachone to cause γH2AX formations and cell death in human osteosarcoma cells

References

• Pardee AB, Li YZ, Li CJ. Cancer therapy with beta-lapachone. Curr Cancer Drug Targets 2002; 2: 227–242
   PubMed Web of Science ®Google Scholar
• Planchon SM, Pink JJ, Tagliarino C, Bornmann WG, Varnes ME, Boothman DA. Beta-lapachone-induced apoptosis in human prostate cancer cells: Involvement of NQO1/xip3. Exp Cell Res 2001; 267: 95–106
   PubMed Web of Science ®Google Scholar
• Pink JJ, Planchon SM, Tagliarino C, Varnes ME, Siegel D, Boothman DA. NAD(P)H:quinone oxidoreductase activity is the principal determinant of beta-lapachone cytotoxicity. J Biol Chem 2000; 2755416–5424
   Google Scholar
• Tagliarino C, Pink JJ, Dubyak GR, Nieminen AL, Boothman DA. Calcium is a key signaling molecule in beta-lapachone-mediated cell death. J Biol Chem 2001; 276: 19150–19159
   PubMed Web of Science ®Google Scholar
• Pink JJ, Wuerzberger-Davis S, Tagliarino C, Planchon SM, Yang X, Froelich CJ, Boothman DA. Activation of a cysteine protease in MCF-7 and T47D breast cancer cells during beta-lapachone-mediated apoptosis. Exp Cell Res 2000; 255: 144–155
   PubMed Web of Science ®Google Scholar
• Blanco E, Bey EA, Dong Y, Weinberg BD, Sutton DM, Boothman DA, Gao J. Beta-lapachone-containing PEG-PLA polymer micelles as novel nanotherapeutics against NQO1-overexpressing tumor cells. J Control Release 2007; 122: 365–374
   PubMed Web of Science ®Google Scholar
• Dong Y, Chin SF, Blanco E, Bey EA, Kabbani W, Xie XJ, Bornmann WG, Boothman DA, Gao J. Intratumoral delivery of beta-lapachone via polymer implants for prostate cancer therapy. Clin Cancer Res 2009; 15: 131–139
   PubMed Web of Science ®Google Scholar
• Begleiter A, Fourie J. Induction of NQO1 in cancer cells. Methods Enzymol 2004; 382: 320–351
   PubMed Web of Science ®Google Scholar
• Rauth AM, Goldberg Z, Misra V. DT-diaphorase: Possible roles in cancer chemotherapy and carcinogenesis. Oncol Res 1997; 9:339–349
   PubMedGoogle Scholar
• Ross D, Siegel D. NAD(P)H:Quinone oxidoreductase 1 (NQO1, DT-diaphorase), functions and pharmacogenetics. Methods Enzymol 2004; 382: 115–144
   PubMed Web of Science ®Google Scholar
• Siegel D, Beall H, Senekowitsch C, Kasai M, Arai H, Gibson NW, Ross D. Bioreductive activation of mitomycin C by DT-diaphorase. Biochemistry 1992; 31: 7879–7885
   PubMed Web of Science ®Google Scholar
• Robertson N, Stratford IJ, Houlbrook S, Carmichael J, Adams GE. The sensitivity of human tumour cells to quinone bioreductive drugs: What role for DT-diaphorase?. Biochem Pharmacol 1992; 44:409–412
   PubMedGoogle Scholar
• Loadman PM, Bibby MC, Phillips RM. Pharmacological approach towards the development of indolequinone bioreductive drugs based on the clinically inactive agent EO9. Br J Pharmacol 2002; 137: 701–709
   PubMed Web of Science ®Google Scholar
• Colucci MA, Moody CJ, Couch GD. Natural and synthetic quinones and their reduction by the quinone reductase enzyme NQO1: From synthetic organic chemistry to compounds with anticancer potential. Org Biomol Chem 2008; 6: 637–656
   PubMedGoogle Scholar
• Duvoix A, Delhalle S, Blasius R, Schnekenburger M, Morceau F, Fougère M, Henry E, Galteau MM, Dicato M, Diederich M. Effect of chemopreventive agents on glutathione S-transferase P1-1 gene expression mechanisms via activating protein 1 and nuclear factor kappa B inhibition. Biochem Pharmacol 2004; 68: 1101–1111
   PubMedGoogle Scholar
• Begleiter A, Leith MK, Thliveris JA, Digby T. Dietary induction of NQO1 increases the antitumour activity of mitomycin C in human colon tumours in vivo. Br J Cancer 2004; 91: 1624–1631
   PubMed Web of Science ®Google Scholar
• Beall HD, Murphy AM, Siegel D, Hargreaves RH, Butler J, Ross D. Nicotinamide adenine dinucleotide (phosphate): Quinone oxidoreductase (DT-diaphorase) as a target for bioreductive antitumor quinones: Quinone cytotoxicity and selectivity in human lung and breast cancer cell lines. Mol Pharmacol 1995; 48: 499–504
   PubMed Web of Science ®Google Scholar
• Keyes SR, Fracasso PM, Heimbrook DC, Rockwell S, Sligar SG, Sartorelli AC. Role of NADPH:Cytochrome c reductase and DT-diaphorase in the biotransformation of mitomycin C1. Cancer Res 1984; 44: 5638–5643
   PubMed Web of Science ®Google Scholar
• Fitzsimmons SA, Workman P, Grever M, Paull K, Camalier R, Lewis AD. Reductase enzyme expression across the National Cancer Institute tumor cell line panel: Correlation with sensitivity to mitomycin C and EO9. J Natl Cancer Inst 1996; 88: 259–269
   PubMed Web of Science ®Google Scholar
• Dehn DL, Winski SL, Ross D. Development of a new isogenic cell-xenograft system for evaluation of NAD(P)H:quinone oxidoreductase-directed antitumor quinones: Evaluation of the activity of RH1. Clin Cancer Res 2004; 10: 3147–3155
   PubMed Web of Science ®Google Scholar
• Siegel D, Franklin WA, Ross D. Immunohistochemical detection of NAD(P)H:Quinone oxidoreductase in human lung and lung tumors. Clin Cancer Res 1998; 4: 2065–2070
   PubMed Web of Science ®Google Scholar
• Belinsky M, Jaiswal AK. NAD(P)H:Quinone oxidoreductase1 (DT-diaphorase) expression in normal and tumor tissues. Cancer Metastasis Rev 1993; 12: 103–117
   PubMed Web of Science ®Google Scholar
• Olive PL, Banáth JP. Phosphorylation of histone H2AX as a measure of radiosensitivity. Int J Radiat Oncol Biol Phys 2004; 58: 331–335
   PubMed Web of Science ®Google Scholar
• Bentle MS, Reinicke KE, Bey EA, Spitz DR, Boothman DA. Calcium-dependent modulation of poly(ADP-ribose)poymerase-1 alters cellular metabolisms and DNA repair. J Biol Chem 2006; 281: 33684–33696
   PubMed Web of Science ®Google Scholar
• Choi EK, Terai K, Ji IM, Kook YH, Park KH, Oh ET, Griffin RJ, Lim BU, Kim JS, Lee DS, et al. Upregulation of NAD(P)H:Quinone oxidoreductase by radiation potentiates the effect of bioreductive beta-lapachone on cancer cells. Neoplasia 2007; 9: 634–642
   PubMed Web of Science ®Google Scholar
• Terai K, Dong GZ, Oh ET, Park MT, Gu Y, Song CW, Park HJ. Cisplatin enhances the anticancer effect of beta-lapachone by upregulating NQO1. Anticancer Drugs 2009; 20: 901–909
   PubMed Web of Science ®Google Scholar
• Takahashi A, Matsumoto H, Nagayama K, Kitano M, Hirose S, Tanaka H, Mori E, Yamakawa N, Yasumoto J, Yuki K, et al. Evidence for the involvement of double-strand breaks in heat-induced cell killing. Cancer Res 2004; 64: 8839–8845
   PubMed Web of Science ®Google Scholar
• Hunt CR, Pandita RK, Laszlo A, Higashikubo R, Agarwal M, Kitamura T, Gupta A, Rief N, Horikoshi N, Baskaran R, et al. Hyperthermia activates a subset of ataxia-telangiectasis mutated effectors independent of DNA strand breaks and heat shock protein 70 status. Cancer Res 2007; 67: 2010–3017
   Google Scholar
• Laszlo A. Fleischer I. Heat-induced perturbations of DNA damage signaling pathways are modulated by molecular chaperones. Cancer Res 2009; 69: 2042–2049
   PubMed Web of Science ®Google Scholar
• Laszlo A, Fleischer I. The heat-induced gamma-H2AX response does not play a role in hyperthermic cell killing 2009; 25: 199–209
   Google Scholar
• Jone EL, Oleson JR, Prosnitz LR, Samulski TV, Vujaskovic Z, Yu D, Sanders LL, Dewhirst MW. Randomized trial of hyperthermica and radiation for superficial tumors. J Clin Oncol 2005; 23: 3079–3085
   PubMedGoogle Scholar
• van der Zee J, Gonzalez Gonalez D, van Rhoon GC, van Dijk JD, van Putten WL, Hart AA. Comparison of radiotherapy alone with radiotherapy plus hyperthermia in coally advanced pelvic tumours: A prospective radomised, multicentre trial. Dutch Deep Hyperthermia Group. Lancet 2000; 355: 1119–11125
   PubMed Web of Science ®Google Scholar
• Issels RD. Hyperthermia adds to chemotherapy. Eur J Cancer 2008; 44: 2546–2554
   PubMed Web of Science ®Google Scholar
• Song CW, Park HJ, Griffin RJ. Improvement of tumor oxygenation by mild hyperthermia. Radiat Res 2001; 155: 515–528
   PubMed Web of Science ®Google Scholar
• Park HJ, Choi EK, Choi J, Ahn KJ, Kim EJ, Ji IM, Kook YH, Ahn SD, Williams B, Griffin R, Boothman DA, Lee CK, Song CW. Heat-induced up-regulation of NAD(P)H:Quinone oxidoreductase potentiates anticancer effects of beta-lapachone. Clin Cancer Res 2005; 11: 8866–8871
   PubMed Web of Science ®Google Scholar
• Song CW, Chae JJ, Choi EK, Hwang TS, Kim C, Lim BU, Park HJ. Anti-cancer effect of bio-reductive drug beta-lapachone is enhanced by activating NQO1 with heat shock. Int J Hyperthermia 2008; 24: 161–169
   PubMed Web of Science ®Google Scholar
• Fletcher CDM, Unni KK, Mertens F. Conventional osteosarcoma. World Health Organization classification of tumors. Pathology and genetics of tumours of soft tissue and bone, AK Raymond, AG Ayala, S Knuutila. IARC Press, Lyon 2002; 264–270
   Google Scholar
• Bacci G, Longhi A, Versari M, Mercuri M, Briccoli A, Picci P. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer 2006; 106: 1154–1161
   PubMed Web of Science ®Google Scholar
• Liu TJ, Lin SY, Chau YP. Inhibition of poly (ADP-ribose) polymerase activation attenuates beta-lapachone-induced necrotic cell death in human osteosarcoma cells. Toxicol Appl Pharmacol 2002; 182: 116–125
   PubMedGoogle Scholar
• Park HJ, Lyon JC, Ohtsubo T, Song CW. Cell cycle progression and apoptosis after irradiation in an acidic environment. Cell Death Diff 2000; 7: 202–207
   Google Scholar